Mr. Speaker, as the member points out, there is a difference between the medical isotopes being produced at a reactor and those at the end of line with respect to the medical establishment.
Indeed, we are working not only with the reactor groups, we are working with companies in the United States. We had a very important and very successful meeting in the United States on Friday. We are collaborating, and we are working together to deal with this on a continental basis.